Israel’s Elgan Pharma (see here previously) has been awarded a 2.36 million euros grant by the European Innovation Council. It will support a Phase III study of its ELGN-GL oral insulin-based formulation that helps the development of a preemie’s gastrointestinal … Continue reading →

The ELGN-GI insulin formulation developed by Israel’s Elgan can save the lives of preterm babies with immature stomachs that cause feeding intolerance. It will avoid the adverse effects of intravenous nutrition, which often leads to infection and liver problems. A … Continue reading →